ClinicalTrials.gg
CompletedNCT05897190Updated Mar 25, 2024

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

A Phase 1 interventional study of SARS-CoV-2 mRNA vaccine (RBMRNA-405) and CoronaVac® in SARS-CoV-2, sponsored by Argorna Pharmaceuticals Co., LTD. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by Argorna Pharmaceuticals Co., LTD · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled May 2022, registered May 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.

02

Conditions studied

  • SARS-CoV-2
03

In context

Lead sponsor

Argorna Pharmaceuticals Co., LTD is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years and older, (BMI) is between 18-30, able to provide legal proof of identity
  2. Participants voluntarily agreed to participate in the study and signed an form
  3. The subject has the ability to understand the study process and is willing and able to comply with all study proposals and other requirements of the study
  4. Be willing and able to comply with protocol and complete 12-month study follow-up
  5. Have received 2 doses of inactivated SARS-CoV-2 vaccine for 6 months and less than 12 months before enrollment
  6. Male and female subjects of childbearing age agree to use effective from screening period until 12 months after vaccination; female subjects of childbearing age have taken effective contraceptive measures 1 month before enrollment
  7. Female subjects of childbearing age are not at pregnant period (negative result of pregnancy test) or lactation period
  8. Male and female subjects of child-bearing age agree that do not donate eggs (eggs, oocytes) for assisted reproduction (female subjects of reproductive age) or avoid sperm donation (male subjects) from screening period until 12 months after vaccination

Exclusion criteria

Exclusion Criteria:

  1. Have received any SARS-CoV-2 vaccines other than 2 doses of the inactivated vaccine
  2. History of Severe Acute Respiratory Syndrome (SARS), Coronavirus disease 2019 (COVID-19), Middle East Respiratory Syndrome (MERS) and other human coronavirus infections or disease
  3. Positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test
  4. The vital signs or physical examination are abnormal as determined by the investigators in screening
  5. Fever (axillary temperature≥37.3°C) on the day of the vaccination
  6. A history of severe allergy (including drugs, vaccines, and foods) or to any component of the experimental vaccine, e.g., allergic shock, laryngeal edema, anaphylactoid purpura, dyspnea, and angioedema, etc.
  7. Subjects have to intramuscular injection, such as having been diagnosed with thrombocytopenia, any blood clotting disorder, or receiving anticoagulant therapy
  8. Subjects have been diagnosed with a serious disease, congenital malformation or chronic disease (including but not limited to respiratory disease or bronchitis such as asthma, serious cardiovascular disease, serious cerebrovascular disease, kidney disease, serious or uncontrollable diabetes, disease, thrombocytopenic purpura, thalassemia, malignant tumor, hereditary allergic constitution, etc.) that may interfere with the conduct or completion of the study
  9. Diagnosed with diseases may affect immune system function, including malignant tumor, congenital or acquired immune deficiency or suppression (e.g., tuberculosis, (HIV)), , , syphilis infection, uncontrollable autoimmune disease, no spleen or spleen dysfunction
  10. History or family history of central nervous system disease, convulsions or tics, epilepsy, meningitis, neurological disorders, mental disorders, cerebritis, myelitis, Guillain-Barre syndrome, etc
  11. Long-term use of immunopotentiator or therapy within 6 months prior to vaccination (continuous oral or injection for more than 14 days)
  12. Use of any blood or blood-related products (e.g., blood transfusion, use of human albumin, human immunoglobulin, etc.) or have received solid organ or bone marrow transplantation within 3 months prior to vaccination
  13. Lymph node - related diseases (such as lymphadenitis, lymph node adhesion, lymph node tuberculosis, tumor , etc.) or skin scars and fistulas at the lymph node site, or lymphadenopathy, tenderness, skin redness and swelling at the lymph node site within 7 days prior to vaccination
  14. Within 3 days prior to vaccination, an acute illness or attack of a chronic disease, or the use of antipyretic analgesic or anti - allergic drugs
  15. Other vaccines have been administered within 4 weeks prior to the trial vaccination or other vaccination schedule (except for emergency vaccinations such as Rabies vaccine and Tetanus vaccine) between the screening period and 28 days after the vaccination
  16. Participating in or planning to participate in other clinical trials (drugs or vaccines) within 3 months prior to participating in this study
  17. Any blood loss >400 mL (e.g., donation of blood or blood components or injury) within 28 days prior to the screening visit, or plans to donate blood or blood components between the screening visit and 28 days post-vaccination
  18. Any abnormal or permanent body art (such as tattoos) at the site of the vaccination, which the researchers think to interfere with observing local reactions at the site of the vaccination
  19. Other circumstances considered by the investigator as inappropriate to participate in the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    SARS-CoV-2 mRNA vaccine (RBMRNA-405) adult group

    One dose was administered by intramuscular injection on day 1

    Biological: SARS-CoV-2 mRNA vaccine (RBMRNA-405)

  • Experimental
    SARS-CoV-2 mRNA vaccine (RBMRNA-405) older adult group

    One dose was administered by intramuscular injection on day 1

    Biological: SARS-CoV-2 mRNA vaccine (RBMRNA-405)

  • Active comparator
    CoronaVac® adult group

    One dose was administered by intramuscular injection on day 1

    Biological: CoronaVac®

  • Active comparator
    CoronaVac® older adult group

    One dose was administered by intramuscular injection on day 1

    Biological: CoronaVac®

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of solicited local and systemic adverse events (AE)

    Time frame: Within 14 days after booster vaccination

Secondary outcomes

  1. Incidence of serious adverse events (SAEs)

    Time frame: Within 360 days after booster vaccination

  2. The levels of neutralizing antibodies anti-SARS-CoV-2

    Time frame: The 14th day, 28th day after booster vaccination

  3. The levels of Immunoglobulin G (IgG) antibody against the S protein of SARS-CoV-2

    Time frame: The 7th day, 14th day, 28th day, 90th day, 180th day and 360th day after booster vaccination

07

Study locations

1 site
  • Chengdu Xinhua Hospital affiliated to North Sichuan Medical College
    Chengdu, Sichuan, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Jun 2022, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2023
First posted
Jun 9, 2023
StartActual
May 16, 2022
Primary completionActual
Jun 13, 2022
CompletionActual
May 12, 2023
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05897190
Lead sponsor
Argorna Pharmaceuticals Co., LTD
Responsible party
Sponsor
First posted
Jun 9, 2023
Start date
May 16, 2022
Primary completion
Jun 13, 2022
Completion
May 12, 2023
Last update
Mar 25, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA COVID-19 Vaccine

Start the discussion